In Entwicklung
Gesundheit·13.6.2026KI-Zusammenfassung
Revolution Medicines' Experimental Drug Doubles Survival in Advanced Pancreatic Cancer
Revolution Medicines' experimental drug, daraxonrasib, has shown unprecedented success in treating advanced pancreatic cancer, doubling patient survival rates and significantly reducing the risk of death by 60% compared to standard chemotherapy. The drug, a first-in-class RAS(ON) inhibitor, targets specific RAS gene mutations and demonstrated a remarkable improvement in tumor shrinkage and patient quality of life, with a much lower incidence of severe side effects. The FDA has granted it expanded access and speedy review.
C
Cumhuriyet4 Min. Lesezeit
